Ocular surface vasculature

Ocular surface vasculature refers collectively to the network of blood and lymphatic vessels supplying the outermost structures of the eye, including the conjunctiva, limbus, and cornea. This system is essential for delivering nutrients, removing waste products, and supporting immune surveillance on the ocular surface. The main arterial supply derives from branches of the ophthalmic artery—primarily anterior ciliary arteries—while venous drainage occurs via episcleral veins[1][3][7]. Lymphatic vessels are also present on the ocular surface and play a role in fluid balance and immune cell trafficking[4]. Under normal conditions, most of the cornea remains avascular to maintain transparency; however, pathological processes such as inflammation or infection can induce neovascularization. While components like VEGF are therapeutic targets in diseases involving abnormal vessel growth (e.g., pterygium or neovascularization), "ocular surface vasculature" itself is not a single molecular entity or canonical therapeutic target but rather an anatomical/functional system composed of multiple vessel types[1][3][4]. Therefore, it does not fit standard definitions for molecular drug targets such as receptors or enzymes. Note: The term "ocular surface vasculature" is anatomically descriptive rather than denoting a specific molecule or receptor. It encompasses various blood and lymphatic vessels but does not refer to a discrete protein target amenable to direct pharmacologic modulation. For structured data purposes, this entry should be flagged as incorrect if used as a molecular target name.

Inhibition of vascular endothelial growth factor (VEGF) signaling [inferred from antiangiogenic therapy]